SARS-CoV-2 IgM testing for travellers: a private pathology perspective from New South Wales and the Australian Capital Territory, Australia
Pathology
.
2022 Jun;54(4):501-503.
doi: 10.1016/j.pathol.2022.03.001.
Epub 2022 Apr 16.
Authors
Michael C Wehrhahn
1
,
Gretschen Millan
2
,
James P Newcombe
2
,
Matthew Long
3
,
Caitlin Keighley
4
,
Paul Whiting
3
,
Ian Chambers
2
Affiliations
1
Douglass Hanly Moir Pathology, Sydney, NSW, Australia. Electronic address: mwehrhahn@dhm.com.au.
2
Douglass Hanly Moir Pathology, Sydney, NSW, Australia.
3
Capital Pathology, Canberra, ACT, Australia.
4
Southern IML Pathology, Wollongong, NSW, Australia (Sonic Healthcare Practices).
PMID:
35440367
PMCID:
PMC9012948
DOI:
10.1016/j.pathol.2022.03.001
No abstract available
Publication types
Letter
MeSH terms
Antibodies, Viral
Australia
Australian Capital Territory
COVID-19* / diagnosis
Humans
Immunoglobulin M
New South Wales
SARS-CoV-2*
Substances
Antibodies, Viral
Immunoglobulin M